Is There Hope for CannTrust (TSX:TRST) Investors After a 6% Gain Last Month?

What’s next for CannTurst investors after a 90% decline in market value?

question marks written reminders tickets

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s premium investing services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn moresdf

We know several cannabis stocks continued to decline in October 2019 to touch new 52-week lows. CannTrust (TSX:TRST)(NYSE:CTST) surprisingly has gained over 6% since the end of September 2019.

CannTrust stock is currently trading at $1.58, which is 90% below its record high. The company was accused of growing cannabis in unlicensed facilities in July, which prompted an investigation from two Canadian regulatory bodies — Health Canada and Ontario Securities Commission.

In September, Health Canada partially suspended CannTrust’s licence, prohibiting the company from selling and producing cannabis. CannTrust is still allowed to cultivate and harvest existing marijuana crops.

CannTrust soon outlined a detailed set of guidelines to revoke this suspension. The company claimed to have identified measures to ensure growing and selling cannabis products in line with existing regulations.

These steps included increasing employee awareness and inventory tracking. CannTrust also destroyed $65 million worth of inventory last month, which were unauthorized as per its licence.

It is quite clear that CannTrust is looking to rebuild the trust with the regulatory bodies and wants to get its licence reinstated as soon as possible. In September 2019, CannTrust had to let go of 20% of its workforce in a bid for survival. This will give the company some breathing space, as the lay-offs will result in cost savings of $9 million.

CannTrust is revamping its board of directors

Last week, CannTrust’s press release stated that the company is in the process of renewing its board of directors. John Kaden resigned as a board member, a position he held since October 2018. Kaden was part of the Special Committee that was created to investigate the causes of CannTrust’s non-compliance with Health Canada regulations.

Kaden stated, “With its remediation plan now underway, I believe CannTrust is well positioned to fulfill its commitments to both bring the company into full regulatory compliance and seek the full reinstatement of its licences. I was honoured to work with the Special Committee to help place CannTrust in this position.”

CannTrust will also search for additional executive team members that also includes a permanent CEO.

What next for CannTrust and investors?

CannTrust provided an update of its remediation plan on October 24. It has submitted a detailed plan to Health Canada and expects to complete all activities described in the plan by March 2020. The plan includes details about a comprehensive internal training program, a strong governance and operations framework, and infrastructure enhancements.

CannTrust aims to recover all unauthorized cannabis products sold from retailers and distributors that have not been sold to the end consumer. The company will be reducing its workforce further to align with reduced operations.

CannTrust is trying its best to gets the licence ban revoked. But it might all be too late if Health Canada goes ahead with a permanent suspension. CannTrust will also have to make sure that its stock price does not fall below $1 in order to be listed on the New York Stock Exchange.

Investors who bought CannTrust shares in the past year have nothing more to lose but everything to gain in case the company is authorized to start producing marijuana once again.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

The Motley Fool recommends CannTrust Holdings and CannTrust Holdings Inc. Fool contributor Aditya Raghunath has no position in any of the stocks mentioned.

More on Cannabis Stocks

Cannabis smoke
Cannabis Stocks

Canopy Growth Stock: Is Now a Good Time to Invest?

The road ahead is highly uncertain for Canopy Growth, as the stock is plagued with losses and seemingly unsurmountable industry…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

TLRY Stock: Should You Invest Now?

TLRY is a Canadian cannabis stock which is trading 91% below record highs. Let's see if you should own TLRY…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Is Tilray Stock a Buy in February 2023?

Despite the volatile cannabis sector, Tilray could be a superb buy for long-term investors.

Read more »

Young woman sat at laptop by a window
Cannabis Stocks

Is SNDL Stock a Buy in February 2023?

SNDL is a beaten-down cannabis stock. While its revenue growth is exceptional, a weak balance sheet has driven stock prices…

Read more »

A cannabis plant grows.
Cannabis Stocks

TLRY Stock: Here’s What’s Coming in 2023

Tilray Inc. (TSX:TLRY) is geared up for big growth this decade and looks like one of the top cannabis stocks…

Read more »

A person holds a small glass jar of marijuana.
Cannabis Stocks

Canopy Growth Stock: Here’s What’s Coming in 2023

Canopy Growth stock has made a lot of new moves in the last few months, but where is the company…

Read more »

A cannabis plant grows.
Cannabis Stocks

Better Cannabis Buy: Canopy Growth Stock or Tilray?

Only two TSX weed stocks can deliver substantial returns in the highly anticipated growth of the global cannabis market.

Read more »

Medicinal research is conducted on cannabis.
Cannabis Stocks

Is Tilray Stock a Buy in January 2023?

Tilray stock has lost 50% of its value in the last 12 months, in line with its peers.

Read more »